Exhibit 99.1



Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

and Provides Business Update


Company anticipates proof of concept data in 2015

and is well capitalized following recent financing that generated $48.2 million


SAN DIEGO — March 11, 2015 — Mirati Therapeutics, Inc. (“Mirati”) (NASDAQ: MRTX) today reported financial results for the fourth quarter and twelve months ended December 31, 2014 and provided an update on its drug development programs.


“Mirati was built on the premise that the best way to improve outcomes for patients with cancer is to treat the specific genetic and epigenetic drivers of their cancer,” said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. “In 2014, we made significant progress across our clinical programs in non-small cell lung cancer, bladder cancer and diffuse large B-cell lymphoma, and are now well positioned for a truly transformational year in 2015. By mid-year, we anticipate having initial data from the MGCD265 and mocetinostat trials, giving us the potential to initiate registration trials by the end of the year.”


2014 and Recent Pipeline Highlights



·                  Successfully completed public offering of 2.6 million shares of common stock at $20.00 per share in February 2015, generating net proceeds of approximately $48.2 million

·                  Strengthened and diversified the board of directors with the addition of William R. Ringo and Michael Grey


MGCD265: Molecularly targeted kinase inhibitor

·                  Identified the recommended Phase 2 dose that, based on pharmacokinetic and pharmacodynamic (PK/PD) results, fully inhibits MET and Axl (which are drivers of tumor growth)

·                  Dosed the first patients selected for MET and Axl genetic alterations. This included patients with non-small cell lung cancer (NSCLC) and patients with solid tumors other than NSCLC

·                  Anticipate initial proof of concept data in mid-2015


Mocetinostat: Molecularly targeted epigenetic inhibitor

·                  Established a novel patient selection strategy based on the identification and selection of patients with inactivating mutations in the histone acetyl transferase genes, CREBBP and EP300

·                  Dosed the first patients who harbor these mutations in two Phase 2 trials: One trial in patients with bladder cancer and the other trial in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

·                  Anticipate initial proof of concept data in mid-2015


MGCD516: Molecularly targeted kinase inhibitor

·                  Initiated a Phase 1 dose escalation study designed to identify an optimal dose capable of inhibiting tumor growth in patients with genetic alterations of Trk, RET or DDR

·                  We plan to establish a Phase 2 dose in the first half of 2015 and initiate expansion cohorts in selected patients in the second half of 2015



The following information was filed by Mirati Therapeutics, Inc. (MRTX) on Wednesday, March 11, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Mirati Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mirati Therapeutics, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account